Editor's Note: The 2026 European Society for Medical Oncology (ESMO) Congress will be held from October 23–27 in Madrid, Spain. As one of the most influential academic meetings in global oncology, ESMO attracts tens of thousands of leading experts each year and provides a platform for cross-border and multidisciplinary scientific exchange through a combination of online and in-person formats.The ESMO official website has now released the titles of oral presentations and posters, while late-breaking abstracts (LBAs) have not yet been announced. In the field of hematologic oncology, more than 26 studies from China have been selected this year, including three oral presentations, multiple formal posters, and numerous ePosters. These studies cover a broad range of hematologic malignancies, including multiple myeloma, chronic lymphocytic leukemia/small lymphocytic lymphoma, acute myeloid leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, peripheral T-cell lymphoma, Burkitt lymphoma, primary central nervous system lymphoma, and Hodgkin lymphoma.
The selected studies highlight several cutting-edge approaches, including bispecific antibodies, fourth-generation BTK inhibitors, antibody-drug conjugates (ADCs), rapid CAR-T manufacturing, proteolysis-targeting chimeras (PROTACs), and machine-learning prediction models, underscoring the rapid growth and emerging leadership potential of China in innovative drug development and clinical research in hematologic oncology.
Hematology Frontier has compiled the relevant information for reference. (If there are any omissions or inaccuracies, please feel free to leave a comment and let us know.)
Oral Presentations
Abstract No.: 1456O
English Title: A first-in-human phase I study of LBL-034, a GPRC5D/CD3 bispecific antibody, in relapsed/refractory multiple myeloma (RRMM)
Chinese Title: GPRC5D/CD3 bispecific antibody LBL-034 in relapsed/refractory multiple myeloma: a first-in-human phase I clinical study
Presenter: Professor Xuelin Dou
Institution: Department of Hematology, Peking University People’s Hospital
Abstract No.: 1457O
English Title: First Report of a Phase Ib Study of Rocbrutinib, a Fourth-Generation Bruton’s Tyrosine Kinase Inhibitor, Combined with R-CHOP in Patients with Previously Untreated B-Cell Lymphoma
Chinese Title: First report of a phase Ib clinical study of the fourth-generation BTK inhibitor rocbrutinib combined with R-CHOP in patients with previously untreated B-cell lymphoma
Presenter: Professor Qingqing Cai
Institution: Lymphoma Center, Sun Yat-sen University Cancer Center
Abstract No.: 1458O
English Title: Safety and Efficacy of TRS005, a Novel Anti-CD20 Antibody-Drug Conjugate, in Patients with Transformed Diffuse Large B-Cell Lymphoma: Results from a Phase I Study
Chinese Title: Safety and efficacy of the novel anti-CD20 antibody-drug conjugate (ADC) TRS005 in patients with transformed diffuse large B-cell lymphoma: results from a phase I clinical study
Presenter: Professor Yuankai Shi
Institution: Cancer Hospital, Chinese Academy of Medical Sciences
Poster Presentations
Diffuse Large B-Cell Lymphoma
Abstract No.: 1475P
English Title: Clinical, Genetic, and Immune Microenvironmental Landscapes of Primary Breast Diffuse Large B-Cell Lymphoma: A Comparative Study with Nodal and Immune-Privileged Site DLBCL
Chinese Title: Clinical, genetic, and immune microenvironmental characteristics of primary breast diffuse large B-cell lymphoma: a comparative study with nodal and immune-privileged site DLBCL
Presenter: Professor Junlei Jia
Institution: Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital
Marginal Zone Lymphoma
Abstract No.: 1465P
English Title: A Phase II Trial of Orelabrutinib Combined with New CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma: A Multicenter, Single-Arm Study (ZOOM Trial) Results Update
Chinese Title: Updated results of the phase II multicenter, single-arm ZOOM trial of orelabrutinib combined with a novel CD20 monoclonal antibody as first-line therapy for previously untreated marginal zone lymphoma
Presenter: Professor Zhiming Li
Institution: Sun Yat-sen University Cancer Center
Peripheral T-Cell Lymphoma
Abstract No.: 1464P
English Title: A Phase II Clinical Study of Liposomal Mitoxantrone Combined with Azacitidine in Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma
Chinese Title: A phase II clinical study of liposomal mitoxantrone combined with azacitidine in relapsed/refractory angioimmunoblastic T-cell lymphoma
Presenter: Professor Huijing Wu
Institution: Hubei Cancer Hospital
Abstract No.: 1466P
English Title: Mitoxantrone Hydrochloride Liposome Combined with COEP (CMOEP) as First-Line Therapy for Peripheral T-Cell Lymphoma: Interim Results of the Phase II COMPASS Trial
Chinese Title: Mitoxantrone hydrochloride liposome combined with COEP (CMOEP) as first-line therapy for peripheral T-cell lymphoma: interim results of the phase II COMPASS trial
Presenter: Jingwei Yu
Location: Tianjin
Mantle Cell Lymphoma
Abstract No.: 1467P
English Title: Orelabrutinib, Lenalidomide, and Rituximab as Frontline Therapy for Mantle Cell Lymphoma: Results of the Phase II POLARIS Study
Chinese Title: Orelabrutinib, lenalidomide, and rituximab as frontline therapy for mantle cell lymphoma: results of the phase II POLARIS study
Presenter: Professor Zheng Song
Institution: Tianjin Medical University Cancer Institute and Hospital
Abstract No.: 1487P
English Title: Proteolysis-Targeting Chimera (PROTAC) Targeting Bruton Tyrosine Kinase (BTK) Degradation in Mantle Cell Lymphoma
Chinese Title: Application of a proteolysis-targeting chimera (PROTAC) targeting BTK degradation in mantle cell lymphoma
Presenter: Professor Xiaohui Wang
Institution: Tianjin Medical University Cancer Institute and Hospital
Transformed Follicular Lymphoma
Abstract No.: 1490P
English Title: Single-Cell Analysis and Functional Profiling Reveal Galectin-3–Driven Reprogramming of the Tumor Immune Microenvironment in Transformed Follicular Lymphoma
Chinese Title: Single-cell analysis and functional profiling reveal Galectin-3-driven reprogramming of the tumor immune microenvironment in transformed follicular lymphoma
Presenter: Professor Junlei Jia
Institution: Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital
Primary Central Nervous System Lymphoma
BTK Inhibitor Real-World Study
Primary Central Nervous System Lymphoma
Abstract No.: 1496P
English Title: Real-World Studies on the Efficacy and Safety of Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Primary Central Nervous System Lymphoma
Chinese Title: Real-world efficacy and safety of Bruton’s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma
Presenter: Tiange Lu
Institution: Shandong Provincial Hospital
Burkitt Lymphoma
Abstract No.: 1497P
English Title: “Dual-Switch” Sequential CAR-T Therapy Overcomes Resistance in Relapsed/Refractory Burkitt Lymphoma: Clinical Efficacy and Cellular Kinetics
Chinese Title: “Dual-switch” sequential CAR-T therapy overcomes resistance in relapsed/refractory Burkitt lymphoma: clinical efficacy and cellular kinetics
Presenter: Professor Guoai Su
Institution: Beijing GoBroad Borun Hospital
B-Cell Malignancies — CAR-T
Abstract No.: 1499P
English Title: Updated Safety and Efficacy of Fast-In-Time (FIT) Anti-CD19 CAR T—A Non-Viral, 2-Day Rapid Manufacture CAR T-Cell Therapy in B-Cell Malignancies
Chinese Title: Updated safety and efficacy of fast-in-time (FIT) anti-CD19 CAR-T, a non-viral, 2-day rapid-manufacturing CAR-T-cell therapy, in B-cell malignancies
Presenter: Professor Ping Li
Institution: Department of Hematology, Tongji Hospital, Tongji University
T-Cell Lymphoma — Epigenetic Regulation and Immunotherapy
Abstract No.: 1460P
English Title: Chidamide-Mediated Epigenetic Reprogramming Improves the Anti-Lymphoma Efficacy of Allogeneic CAR-γδT Cells
Chinese Title: Chidamide-mediated epigenetic reprogramming improves the anti-lymphoma efficacy of allogeneic CAR-γδT cells
Presenter: Jiayi Han
Location: Tianjin
Survival Follow-Up in Lymphoma Patients — Nursing/Psychological Care
Abstract No.: CN66
English Title: A Study on Latent Classes and Influencing Factors of Fear of Disease Progression in Lymphoma Patients During the Survival Follow-Up Period
Chinese Title: Latent classes and influencing factors of fear of disease progression among lymphoma patients during the survival follow-up period
Presenter: Li N. Feng
Location: Tianjin
ePoster Presentations
Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Abstract No.: 1502eP
English Title: Predicting Bruton’s Tyrosine Kinase Inhibitor Therapy Failure in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Using Machine Learning
Chinese Title: Machine learning-based prediction of Bruton’s tyrosine kinase inhibitor treatment failure in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
Presenter: Yutang Li
Institution: Shandong Provincial Hospital
Abstract No.: 1506eP
English Title: Sustained Benefit of Orelabrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia: Up to 5 Years of Follow-Up from a Phase 2 Study
Chinese Title: Sustained benefit of orelabrutinib in relapsed/refractory chronic lymphocytic leukemia: up to 5 years of follow-up from a phase II study
Presenter: Professor Wei Xu
Institution: The First Affiliated Hospital of Nanjing Medical University
Acute Myeloid Leukemia
Acute Myeloid Leukemia
Abstract No.: 1505eP
English Title: Exosomal circRNF220 Engages ACLY to Drive AML Progression via Metabolic-Epigenetic Programming of M2 Macrophages and CD47-Dependent Immune Evasion
Chinese Title: Exosomal circRNF220 drives acute myeloid leukemia progression through metabolic-epigenetic reprogramming of M2 macrophages and CD47-dependent immune evasion
Presenter: Hanyang Wu
Location: Jinan
Aggressive B-Cell Lymphoma
Abstract No.: 4574eP
English Title: Indandione-Based Drugs Target USP8 to Promote SLC7A11 Ubiquitination and Degradation, Selectively Inducing Ferroptosis in TP53R175H-Mutant Aggressive B-Cell Lymphoma
Chinese Title: Indandione-based compounds target USP8 to promote SLC7A11 ubiquitination and degradation, selectively inducing ferroptosis in TP53R175H-mutant aggressive B-cell lymphoma
Presenter: Wenhua Wang
Location: Tianjin
Primary Central Nervous System Lymphoma
Abstract No.: 764eP
English Title: Development and Internal Validation of a Dynamic Prognostic Nomogram for Primary Central Nervous System Lymphoma
Chinese Title: Development and internal validation of a dynamic prognostic nomogram for primary central nervous system lymphoma
Presenter: Zhicheng Chai
Location: Luohe
Diffuse Large B-Cell Lymphoma
Abstract No.: 1511eP
English Title: Real-World Efficacy and Safety of Zuberitamab-Based Regimens in Previously Untreated Diffuse Large B-Cell Lymphoma: A Retrospective Single-Center Study
Chinese Title: Real-world efficacy and safety of zuberitamab-based regimens in previously untreated diffuse large B-cell lymphoma: a retrospective single-center study
Presenter: Hanguo Guo
Location: Guangzhou
Abstract No.: 1528eP
English Title: Real-World Efficacy and Safety of Glofitamab-Based Regimens in Diffuse Large B-Cell Lymphoma
Chinese Title: Real-world efficacy and safety of glofitamab-based regimens in diffuse large B-cell lymphoma
Presenter: Liufang Gu
Location: Xi’an
Non-Hodgkin Lymphoma — Supportive Care
Abstract No.: 4034eP
English Title: Telpegfilgrastim in Elderly Patients with Non-Hodgkin Lymphoma for Primary Prophylaxis of Chemotherapy-Induced Neutropenia: A Prospective Study
Chinese Title: Telpegfilgrastim for primary prophylaxis of chemotherapy-induced neutropenia in elderly patients with non-Hodgkin lymphoma: a prospective study
Presenter: Hongming He
Location: Fuzhou
Abstract No.: 4051eP
English Title: Efficacy and Safety of Telpegfilgrastim for Preventing Chemotherapy-Induced Neutropenia in Patients with Hematological Malignancies at Intermediate-to-High Risk of Febrile Neutropenia: A Prospective Real-World Study
Chinese Title: Efficacy and safety of telpegfilgrastim for preventing chemotherapy-induced neutropenia in patients with hematological malignancies at intermediate-to-high risk of febrile neutropenia: a prospective real-world study
Presenter: Xushu Zhong
Location: Chengdu
Classical Hodgkin Lymphoma
Abstract No.: 1531eP
English Title: Clinical Features and Outcomes of Secondary and Primary Extranodal Classical Hodgkin Lymphoma
Chinese Title: Clinical features and outcomes of primary and secondary extranodal classical Hodgkin lymphoma
Presenter: Jiayi Han
Location: Tianjin
Marginal Zone Lymphoma
Abstract No.: 1515eP
English Title: Orelabrutinib Plus Rituximab Maintenance after Short-Course Chemoimmunotherapy in Intermediate/High-Risk Marginal Zone Lymphoma
Chinese Title: Orelabrutinib plus rituximab maintenance following short-course chemoimmunotherapy in patients with intermediate- or high-risk marginal zone lymphoma
Presenter: Zhilin Gao
Location: Taiyuan
More poster presentations and late-breaking abstract (LBA) details will be covered in subsequent reports following ESMO 2026. Hematology Frontier will continue to bring you the latest developments and highlights from the meeting. Stay tuned.
